|
|
|
| Therapeutic Effect of Dendritic Cell-cytokine-induced Cellular Immunity Combined with TC Chemotherapy on Patients with Stage ⅡB-ⅣA Cervical Cancer |
| JIAO Min, GUO Hui, WANG Shu-hong, et al |
| Department of Oncology, the First Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi, 710061 |
|
|
|
|
Abstract 【Objective】To investigate the efficacy of dendritic cell-cytokine-induced killer (DC-CIK) cell immunization combined with taxol plus carboplatin (TC) chemotherapy in patients with stage IIB-ⅣA cervical cancer. 【Methods】From September 2016 to August 2018, 72 patients with stage ⅡB-ⅣA cervical cancer in our hospital were selected and divided into observation group and control group with 36 cases in each group according to the random number table method. The control group was treated with TC chemotherapy, the observation group was treated with DC-CIK cell immunotherapy on the basis of the control group.Objective remission rate, disease control rate, Th1/Th2 secretion factor (IL-2, IL-10), PI3K / Akt signal transduction pathway index [phosphatidylinositol-3-kinase (PI3K), protein kinase B (Akt), amino terminal kinase 1 (JNK1)], osteopontin (OPN), endothelial glycoprotein (CD105) and the World Health Organization Quality of Life questionnaire summary score (WHOQOL-BREF) were compared between the two groups. 【Results】After 4 cycles of treatment, the objective remission rate and disease control rate of the observation group were 63.89% and 91.67%, respectively, which were significantly higher than 36.11% and 66.67% of the control group; IL-2 was higher than the control group, and IL-10 was lower than the control group; the levels of PI3K, Akt, JNK1, jnk2, JAK2, OPN and CD105 were lower than the control group, and the differences were statistically significant (P<0.05); the WHOQOL-BREF score of the observation group after 4 cycles of treatment was significant. It was higher than that of the control group (P<0.05).【Conclusion】DC-CIK cell immunity combined with TC chemotherapy in the treatment of ⅡB-ⅣA stage cervical cancer can inhibit tumor proliferation, invasion and metastasis, improve the immune function of patients, improve the quality of life of patients, and the effect is significant. The mechanism may be related to the inhibition of PI3K / Akt signal transduction pathway expression.
|
|
Received: 27 May 2019
|
|
|
|
|
|
[1] 茹渤.DC-CIK联合氟尿嘧啶+顺铂化疗对局部进展期宫颈癌术后患者的疗效及安全性[J].现代肿瘤医学,2018,26(23):131-134.
[2] 中华人民共和国国家卫生和计划生育委员会.宫颈癌及癌前病变规范化诊疗指南(试行)[J].慢性病学杂志,2013,5(8):37-46.
[3] Cho WK, Kim YI, Park W,et al.Para-aortic lymph node recurrence after curative radiotherapy for cervical cancer[J].Int J Gynecol Cancer,2019 ,29(7):1116-1120.
[4] 宋晓婕,周艳艳,赵莉娜.加味八珍汤联合放化疗对中晚期宫颈癌疗效及对患者T细胞亚群水平、血清肿瘤标志物表达及生存期的影响[J].中国实验方剂学杂志,2018,24(4):174-179.
[5] 霍忠超,刘晓霞,王雪玲,等.负载肺癌全抗原的自体树突状细胞诱导T细胞反应的体外研究[J].疑难病杂志,2015,14(2):175-178.
[6] 宋默,席姗姗,刘继攀,等.参芪扶正注射液对直肠癌术后化疗患者免疫功能及化疗毒副作用的影响[J].中医药导报,2015,21(2):46-48.
[7] 陈仲波,余红萍,朱笕青,等.合并 HPV 感染宫颈癌患者外周血 Th1/Th2细胞免疫功能变化及临床意义[J].中华医院感染学杂志,2016,26(24):5677-5679.
[8] 卢丹,钱静,孙飞,等.PI3K、Akt、mTOR、p70S6K基因在宫颈癌变过程中的表达及相关性研究[J].中国现代医学杂志,2015,25(2):46-51. |
|
|
|
2019, Vol. 36 
